Rizzolio F - Search Results

1

Kumar V, Palazzolo S, Bayda S, Corona G, Toffoli G, Rizzolio F. Kumar V, et al. Among authors: rizzolio f. Theranostics. 2016 Mar 20;6(5):710-25. doi: 10.7150/thno.14203. eCollection 2016. Theranostics. 2016. PMID: 27022418 Free PMC article. Review.

2

Research highlights. MCL1 and FBW7 as new predictive candidate biomarkers of anti-tubulin agents.

Lucchetti C, Rizzolio F, Castronovo M, Toffoli G. Lucchetti C, et al. Among authors: rizzolio f. Pharmacogenomics. 2011 Oct;12(10):1379-80. doi: 10.2217/pgs.11.112. Pharmacogenomics. 2011. PMID: 22008046 No abstract available.

3

Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets.

Corona G, Rizzolio F, Giordano A, Toffoli G. Corona G, et al. Among authors: rizzolio f. J Cell Physiol. 2012 Jul;227(7):2827-31. doi: 10.1002/jcp.24003. J Cell Physiol. 2012. PMID: 22105661 Review.

4

Research highlights. Protein kinase D3 is the genetic sensitizer of RAF inhibitor RAF265 in melanoma cells.

Lucchetti C, Rizzolio F, Castronovo M, Toffoli G. Lucchetti C, et al. Among authors: rizzolio f. Pharmacogenomics. 2011 Oct;12(10):1380. Pharmacogenomics. 2011. PMID: 22121538 No abstract available.

5

Research highlights. Overcoming BRAF resistance to PLX4032 by AKT inhibition in PTEN-deficient melanoma cells.

Lucchetti C, Rizzolio F, Castronovo M, Toffoli G. Lucchetti C, et al. Among authors: rizzolio f. Pharmacogenomics. 2011 Oct;12(10):1381. Pharmacogenomics. 2011. PMID: 22121540 No abstract available.

6

Research highlights. PI3K/AKT/mTOR inhibitors would require PI3KCA-mutation analysis.

Lucchetti C, Rizzolio F, Castronovo M, Toffoli G. Lucchetti C, et al. Among authors: rizzolio f. Pharmacogenomics. 2011 Oct;12(10):1382. Pharmacogenomics. 2011. PMID: 22121542 No abstract available.

7

Critical choices for modeling breast cancer in transgenic mouse models.

Caligiuri I, Rizzolio F, Boffo S, Giordano A, Toffoli G. Caligiuri I, et al. Among authors: rizzolio f. J Cell Physiol. 2012 Aug;227(8):2988-91. doi: 10.1002/jcp.24031. J Cell Physiol. 2012. PMID: 22170180 Review.

8

Dissecting Pin1 and phospho-pRb regulation.

Rizzolio F, Caligiuri I, Lucchetti C, Fratamico R, Tomei V, Gallo G, Agelan A, Ferrari G, Toffoli G, Klein-Szanto AJ, Giordano A. Rizzolio F, et al. J Cell Physiol. 2013 Jan;228(1):73-7. doi: 10.1002/jcp.24107. J Cell Physiol. 2013. PMID: 22553088

9

Androgen receptor serine 81 mediates Pin1 interaction and activity.

La Montagna R, Caligiuri I, Maranta P, Lucchetti C, Esposito L, Paggi MG, Toffoli G, Rizzolio F, Giordano A. La Montagna R, et al. Among authors: rizzolio f. Cell Cycle. 2012 Sep 15;11(18):3415-20. doi: 10.4161/cc.21730. Epub 2012 Aug 16. Cell Cycle. 2012. PMID: 22894932 Free PMC article.

10

The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor α in breast cancer.

Lucchetti C, Caligiuri I, Toffoli G, Giordano A, Rizzolio F. Lucchetti C, et al. Among authors: rizzolio f. PLoS One. 2013;8(2):e55355. doi: 10.1371/journal.pone.0055355. Epub 2013 Feb 4. PLoS One. 2013. PMID: 23390529 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

154 results

Search Page